{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:33:38Z","timestamp":1791401618361,"version":"4.3.3"},"reference-count":126,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a leading cause of morbidity and mortality in systemic sclerosis, marked by complex immunopathogenic mechanisms and progressive fibrosis. Recent advances have illuminated key cellular players as T cells, macrophages, dendritic cells, and profibrotic mediators such as TGF-\u03b2, PDGF, and CTGF, alongside emerging roles for epigenetic reprogramming in sustaining fibroblast activation. This narrative review synthesizes current understanding of immune-fibrotic crosstalk and critically evaluates both established therapies (e.g., mycophenolate mofetil, nintedanib, tocilizumab, and rituximab) and novel targeted approaches. Particular attention is given to emerging immunomodulatory, antifibrotic, and cell-based therapies, including CAR-T and mesenchymal stem cell treatments, as well as the potential of epigenetic modulators repurposed from oncology. By bridging basic science and clinical practice, this review outlines the evolving therapeutic landscape of SSc-ILD and highlights opportunities for future research and personalized intervention.<\/jats:p>","DOI":"10.1177\/17534666251366023","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T10:03:47Z","timestamp":1755338627000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["The fibrosis puzzle of systemic sclerosis-associated ILD and the quest for targeted interventions"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1650-8928","authenticated-orcid":false,"given":"Bohdana","family":"Doskaliuk","sequence":"first","affiliation":[{"name":"Department of Pathophysiology, Ivano-Frankivsk National Medical University, Halytska str. 2, Ivano-Frankivsk 76018, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liubomyr","family":"Zaiats","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5472-195X","authenticated-orcid":false,"given":"Nazar","family":"Sahan","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Fedorchenko","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6040-8137","authenticated-orcid":false,"given":"Olga","family":"Antymys","sequence":"additional","affiliation":[{"name":"Department of Human Anatomy, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1262-5609","authenticated-orcid":false,"given":"Roman","family":"Yatsyshyn","sequence":"additional","affiliation":[{"name":"Academician Ye. M. Neiko Department of Internal Medicine #1, Clinical Immunology and Allergology, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1551911"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201903-0563CI"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05565-w"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcu.24094"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40862"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/2397198320903867"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2024.11.003"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.2478\/rir-2024-0020"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05535-2"},{"key":"e_1_3_4_11_2","article-title":"M2 macrophage polarization in systemic sclerosis fibrosis: pathogenic mechanisms and therapeutic effects","volume":"9","author":"Hu M","year":"2023","unstructured":"Hu M, Yao Z, Xu L, et al. M2 macrophage polarization in systemic sclerosis fibrosis: pathogenic mechanisms and therapeutic effects. Heliyon 2023; 9: e16206.","journal-title":"Heliyon"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.4078\/jrd.2024.0129"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04658-6"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26062618"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/sclerosis2040021"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05328-z"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01952-8"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02536-5"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14051735"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S285409"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-1999-3"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e35445"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2019.154799"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.826839"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05773-w"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar4430"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-018-0891-z"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2021.03.009"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032963"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13417"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13426"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1254904"},{"key":"e_1_3_4_33_2","first-page":"5","article-title":"Expression of NLRP3 inflammasome, cytokines and vascular mediators in the skin of systemic sclerosis patients","volume":"17","author":"Martinez-Godinez MA","year":"2015","unstructured":"Martinez-Godinez MA, Cruz-Dom\u00ednguez MP, Jara LJ, et al. Expression of NLRP3 inflammasome, cytokines and vascular mediators in the skin of systemic sclerosis patients. Isr Med Assoc J 2015; 17: 5\u201310.","journal-title":"Isr Med Assoc J"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.07.036"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01764-w"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41536-021-00153-z"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.202000168"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2015.154"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14060652"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40139-018-0155-0"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S356877"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226430"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25348"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae394"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05794-5"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202306-1113ST"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00614-2023"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41668"},{"key":"e_1_3_4_50_2","unstructured":"Genentech. Actemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease. https:\/\/www.gene.com\/media\/press-releases\/14897\/2021-03-04\/genentechs-actemra-becomes-the-first-bio (accessed 2025 May 3)."},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223335"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1177\/00368504251333912"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202301-055OC"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1019915"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-024-01773-y"},{"key":"e_1_3_4_56_2","first-page":"89","article-title":"Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis","volume":"10","author":"Inomata M","year":"2015","unstructured":"Inomata M, Nishioka Y, Azuma A. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evid 2015; 10: 89\u201398.","journal-title":"Core Evid"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-005086"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-024-00271-1"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151322"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04565-w"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02347-2021"},{"key":"e_1_3_4_63_2","article-title":"The current landscape of antifibrotic therapy across different organs: a systematic approach","volume":"107245","author":"Fuster-Mart\u00ednez I","year":"2024","unstructured":"Fuster-Mart\u00ednez I, Calatayud S. The current landscape of antifibrotic therapy across different organs: a systematic approach. Pharmacol Res 2024; 107245.","journal-title":"Pharmacol Res"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12206680"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05695-1"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24998"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-220541"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11398"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05628-y"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152366"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05499-9"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.3390\/tomography10040041"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000057"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02013"},{"key":"e_1_3_4_75_2","first-page":"2987","article-title":"Phase I study to evaluate the safety of allogeneic bone marrow derived mesenchymal stem cells for interstitial lung disease in patients with connective tissue disorders","volume":"75","author":"Abril A","year":"2023","unstructured":"Abril A, Mira-Avendano I, Durand N, et al. Phase I study to evaluate the safety of allogeneic bone marrow derived mesenchymal stem cells for interstitial lung disease in patients with connective tissue disorders. Arthritis Rheumatol 2023; 75: 2987\u20132989.","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2025.2489700"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201606-426FR"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells13070635"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60982-3"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6368"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703327"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.2174\/1566523220666201012145731"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2025.1507163"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105338"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02039-0"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203194"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0396-2"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2024.01.007"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22759"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24494"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150871"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1813006116"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells14060433"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000744"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00367-5"},{"key":"e_1_3_4_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpet.2025.103396"},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvq052"},{"key":"e_1_3_4_98_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.39797"},{"key":"e_1_3_4_99_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.5355"},{"key":"e_1_3_4_100_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.42477"},{"key":"e_1_3_4_101_2","unstructured":"Ziritaxestat clinical trials discontinued. https:\/\/sclerodermanews.com\/news\/galapagos-gilead-ziritaxestat-clinical-trials-scleroderma-ipf-discontinued\/ (2021 accessed 2025 May 3)."},{"key":"e_1_3_4_102_2","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/208219"},{"key":"e_1_3_4_103_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202208-1579ED"},{"key":"e_1_3_4_104_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.14151"},{"key":"e_1_3_4_105_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-230019"},{"key":"e_1_3_4_106_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197100"},{"key":"e_1_3_4_107_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02383"},{"key":"e_1_3_4_108_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003500"},{"key":"e_1_3_4_109_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223952"},{"key":"e_1_3_4_110_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725"},{"key":"e_1_3_4_111_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225174"},{"key":"e_1_3_4_112_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1454913"},{"key":"e_1_3_4_113_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03451-1"},{"key":"e_1_3_4_114_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226142"},{"key":"e_1_3_4_115_2","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000000891"},{"key":"e_1_3_4_116_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41812"},{"key":"e_1_3_4_117_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.42677"},{"key":"e_1_3_4_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.06.027"},{"key":"e_1_3_4_119_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000592"},{"key":"e_1_3_4_120_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-022-01067-5"},{"key":"e_1_3_4_121_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141182"},{"issue":"3","key":"e_1_3_4_122_2","first-page":"168","article-title":"Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography","volume":"202","author":"Khanna D","unstructured":"Khanna D, Distler O, Cottin V, et al. Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. J Scleroderma Relat Disord 202; 7(3): 168\u2013178.","journal-title":"J Scleroderma Relat Disord"},{"key":"e_1_3_4_123_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201903-0486OC"},{"key":"e_1_3_4_124_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015936"},{"key":"e_1_3_4_125_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13142437"},{"key":"e_1_3_4_126_2","doi-asserted-by":"publisher","DOI":"10.1186\/s43168-025-00405-2"},{"key":"e_1_3_4_127_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20032512"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666251366023","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17534666251366023","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666251366023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T01:18:04Z","timestamp":1755566284000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17534666251366023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":126,"alternative-id":["10.1177\/17534666251366023"],"URL":"https:\/\/doi.org\/10.1177\/17534666251366023","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/17534666251366023\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251366023\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251366023\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251366023\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251366023\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251366023\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251366023\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"article-number":"17534666251366023"}}